Clinical Trial

A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients

Study acronym: SENEKA
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Heart failure (HF) and Chronic Kidney Disease (CKD) patients are frequently not administered renin-angiotensin aldosterone system inhibitor (RAASi) therapies at recommended doses due to hyperkalaemia, despite proven mortality and morbidity benefits. Sodium zirconium cyclosilicate (SZC) is a nonabsorbed potassium binder proven to lower serum potassium (S-K) and maintain normokalaemia. The purpose is to assess if a treatment regimen containing SZC will allow RAASi therapies to be optimized to target doses in patients with heart failure, chronic kidney disease and elevated serum potassium or at risk of developing elevated serum potassium.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-08-27; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2024-10-07
Trial Details
NCT Number NCT06578078
Lead Sponsor Fundación para la Investigación del Hospital Clínico de Valencia
Conditions Heart Failure, Chronic Kidney Diseases
Enrollment 94 participants
Start Date 2024-10-03
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-04